Clinical Report: The Impact of Single-Pill Combinations on Blood Pressure Management
Overview
Single-pill combinations (SPCs) are underutilized in the management of hypertension, with fewer than 20% of U.S. adults on antihypertensive medications prescribed an SPC.
Background
Hypertension is a leading cause of cardiovascular morbidity and mortality, yet many patients fail to achieve target blood pressure levels. The complexity of multi-pill regimens contributes to poor medication adherence.
Data Highlights
No numerical data provided in the source material.
Key Findings
SPCs can improve adherence and persistence compared to free-equivalent combinations.
A meta-analysis indicated that SPCs reduce blood pressure more effectively than maximum-dose monotherapy.
Triple and quadruple SPCs are more effective at lowering blood pressure than placebo or monotherapy.
Clinical Implications
The updated AHA/ACC guidelines support the use of SPCs in patients with stage 2 hypertension.
Conclusion
The adoption of single-pill combinations in hypertension management is supported by evidence for improved adherence and blood pressure control.
A DOJ settlement resolved allegations involving a cash-pay pain practice in which continued access to controlled-substance prescriptions was tied to recurring payments.
A living clinical guideline outlines a treatment hierarchy for selected pharmacologic therapies in patients with obesity and selected patients with overweight.
